Real-world evidence shows healthcare providers use c2n diagnostics' precivityad® blood test to help affirm alzheimer's disease diagnosis and change drug treatment decisions

St. louis--(business wire)-- #alzheimers--c2n diagnostics, a leader in advanced brain health diagnostics, says new research posted in the online version of annals of clinical and translational neurology (and soon in print form) affirms the clinical utility of its precivityad® blood test, which healthcare providers use to help diagnosis alzheimer's disease (ad). the findings are believed to represent the first prospective, published evidence that clinicians use novel blood biomarker testing in a way that impr.
AFRM Ratings Summary
AFRM Quant Ranking